## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Type Responses)  1. Name and Address of Reporting Person * KIRITSY CHRISTOPHER P			2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [PIRS]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) (First) (Middle) C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 01/25/2020					-	_X Director Officer (giv	ve title below)		6 Owner er (specify below)			
(Street) BOSTON, MA 02109			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(Cit		(State)	(Zip)	Table I - Non-Derivative Securities Acqu				es Acquir	uired, Disposed of, or Beneficially Owned						
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	Executi any	2A. Deemed Execution Date, any (Month/Day/Ye		ransaction e tr. 8)	(A	4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)		wned Follow ransaction(s)			Ownership o Form:	'. Nature of Indirect Beneficial Ownership	
				(WOILLI	/Day/10		ode	V A	mount (A) or		o <sub>l</sub>		or Indirect (I) (Instr. 4) (Instr. 4)		
Reminder:	report on a s						in	this f	s who respo orm are not s a currently	required	to respond	unless the		ned SEC 14	74 (9-02)
Reminder:	Report on a s	•					Pe	rsons	who respo	nd to the	collection	of informa	tion contain	ned SEC 14	74 (9-02)
1. Title of Derivative	2. Conversion		Table II -  3A. Deemed Execution Date, if	( <i>e.g.</i> , pu	ts, calls, 5. N tion of I	warrar umber	in disception discepti	this for splays  Disports, contact Exertation I	orm are not s a currently sed of, or Ber avertible securcisable and Date	required valid ON eficially ( rities)	to respond  B control i  Owned  and Amount rlying	8. Price of Derivative			11. Natu
1. Title of	2.	Date	Table II -  3A. Deemed Execution Date, if	4. Transac Code	ts, calls,  5. N  tion of I  Sec  or I  of (	warrar fumber Derivation curities uired (A Disposed D) tr. 3, 4,	in dis	this for splays  Disports, contact Exertation I	orm are not s a currently sed of, or Bernvertible securcisable and	required valid ON eficially (rities)  7. Title of Unde	to respond IB control in  Owned  and Amount rlying es	unless the number.	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Ownership Form of Derivative Security: Direct (D) or Indirect (s) (I)	11. Nature of Indirection of Seneral Owners (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	Date	Table II -  3A. Deemed Execution Date, if any	4. Transac Code	ts, calls,  5. N tion of I Sec or I of ( (Ins and	fumber Derivati urities uired (Dispose D) tr. 3, 4, 5)	din disception discept	this for splays  Disports, contact Exertation I	sed of, or Bernvertible securcisable and Date //Year)	required valid ON eficially (rities)  7. Title of Unde Securities	to respond IB control in  Owned  and Amount rlying es	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	of 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natu of Indire Benefic Owners (Instr. 4

#### **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
KIRITSY CHRISTOPHER P C/O PIERIS PHARMACEUTICALS, INC. 255 STATE STREET, 9TH FLOOR BOSTON, MA 02109	X				

### **Signatures**

/s/ Marc D. Mantell, Attorney-in-fact	01/28/2020
Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.